Lyell Immunopharma, Inc.
LYEL
$17.92
-$1.10-5.78%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -262.26% | 8.99% | 18.22% | 72.81% | -330.51% |
| Total Depreciation and Amortization | -6.59% | -18.15% | -8.89% | -31.54% | 7.39% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,244.60% | 31.37% | 67.14% | -97.44% | 3,551.49% |
| Change in Net Operating Assets | 594.12% | 84.47% | 90.83% | -28,200.00% | -96.72% |
| Cash from Operations | -12.86% | 17.07% | 37.05% | -15.87% | -34.82% |
| Capital Expenditure | -390.32% | 63.10% | 31.71% | -459.09% | 25.42% |
| Sale of Property, Plant, and Equipment | -90.87% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 221.16% | -75.44% | -81.62% | -17.88% | 4,194.13% |
| Cash from Investing | -1,036.55% | -73.52% | -81.79% | 29.83% | 2,689.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.55% | 27,073.91% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -200.00% | -- | -- |
| Cash from Financing | -99.56% | 27,222.40% | 18,200.00% | -99.77% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -355.91% | 214.54% | -246.84% | 119.84% | 120.23% |